Methods, compositions, and kits for the treatment of medical conditions

a technology for medical conditions and compositions, applied in the field of immunoinflammatory disorders and ophthalmic disorders, can solve the problems of rubbing of bones against each other, and affecting so as to achieve less toxic effects, improve the effect of treatment effect, and reduce the effect of toxic side effects

a technology for medical conditions and compositions, applied in the field of immunoinflammatory disorders and ophthalmic disorders, can solve the problems of rubbing of bones against each other, and affecting so as to achieve less toxic effects, improve the effect of treatment effect, and reduce the effect of toxic side effects

US20070225217A1Inactive Publication Date: 2007-09-27THERAOPTICS
27 Cites 66 Cited by

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods, compositions, and kits for the treatment of medical conditions
  • Methods, compositions, and kits for the treatment of medical conditions
  • Methods, compositions, and kits for the treatment of medical conditions

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0339] The effects of test compound combinations on TNFα secretion were assayed in white blood cells from human buffy coat stimulated with lipopolysaccharide or phorbol 12-myristate 13-acetate (PMA) and ionomycin as follows. The results from these experiments are set forth in FIGS. 1A-1MM.

[0340] Lipopolysaccharide (LPS)

[0341] A 100 μl suspension of diluted human white blood cells contained within each well of a polystyrene 384-well plate (NalgeNunc) was stimulated to secrete TNFα by treatment with a final concentration of 2 μg / mL lipopolysaccharide (Sigma L-4130). Various concentrations of each test compound were added at the time of stimulation. After 16-18 hours of incubation at 37° C. in a humidified incubator, the plate was centrifuged and the supernatant transferred to a white opaque polystyrene 384-well plate (NalgeNunc, Maxisorb) coated with an anti-TNFα antibody (PharMingen, #551220). After a two-hour incubation, the plate washed (Tecan PowerWasher 384) with PBS containing...

example 2

[0344] Both corticosteroids and NsIDIs suppress cytokine production in cell culture models of immune function. We tested the effect of the combination of various concentrations of NsIDIs and corticosteroids on cytokine production in a cell culture model of immune function. We propose that combinations that demonstrate synergistic or superaddative effects can be used to treat ophthalmic disorders at concentrations low enough to avoid undesired side effects.

Assay for Proinflammatory Cytokine-Suppressing Activity

[0345] Compound dilution matrices were assayed for the suppression of IFNγ, IL-2, and TNFα, as described below. The results from these experiments are set forth in FIGS. 2A-2LL.

[0346] IFNγ

[0347] A 100 μL suspension of diluted human white blood cells contained within each well of a polystyrene 384-well plate (NalgeNunc) was stimulated to secrete IFNγ by treatment with a final concentration of 10 ng / mL phorbol 12-myristate 13-acetate (Sigma, P-1585) and 750 ng / mL ionomycin (S...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
timeaaaaaaaaaa
timeaaaaaaaaaa
timeaaaaaaaaaa
Login to View More

Abstract

The invention features methods, compositions, and kits for treating an immunoinflammatory disorder, an ophthalmic disorder, a musculoskeletal disorder or pain associated therewith, a periodontal disease, or a disease or condition associated with an increased serum CRP level.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS [0001] This application claims benefit of U.S. Provisional Application No. 60 / 735,989, filed Nov. 9, 2005, which is hereby incorporated by reference.BACKGROUND OF THE INVENTION [0002] The invention relates to the treatment of immunoinflammatory disorders and ophthalmic disorders. [0003] Immunoinflammatory disorders are characterized by the inappropriate activation of the body's immune defenses. Rather than targeting infectious invaders, the immune response targets and damages the body's own tissues or transplanted tissues. The tissue targeted by the immune system varies with the disorder. For example, in multiple sclerosis, the immune response is directed against the neuronal tissue, while in Crohn's disease the digestive tract is targeted. Immunoinflammatory disorders affect millions of individuals and include conditions such as asthma, allergic intraocular inflammatory diseases, arthritis, atopic dermatitis, atopic eczema, diabetes, hemolyti...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
27 Sep 2007
Publication
US20070225217A1
IPC
A61K38/13; A61K31/573; A61K31/553; A61K31/519; A61K31/557
CPC
A61K9/0014; A61K9/0048; A61K45/06; A61K38/13; A61K9/0051; A61K31/222; A61K31/4015; A61K31/451
Inventors
CHAPPELL, TODD W.; AUSPITZ, BENJAMIN A.